EFFECT OF MULTIPLE-DOSE OMEPRAZOLE ON THE PHARMACOKINETICS OF CARBAMAZEPINE

被引:34
作者
NAIDU, MUR [1 ]
SHOBHA, JC [1 ]
DIXIT, VK [1 ]
KUMAR, A [1 ]
SEKHAR, KR [1 ]
SEKHAR, EC [1 ]
KUMAR, TR [1 ]
机构
[1] NIZAMS INST MED SCI,DEPT GASTROENTEROL,HYDERABAD 500482,ANDHRA PRADESH,INDIA
来源
DRUG INVESTIGATION | 1994年 / 7卷 / 01期
关键词
D O I
10.1007/BF03257393
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics of carbamazepine (CBZ) were studied in 7 patients with duodenal ulcer both before and after 14 days' treatment with omeprazole (20 mg/day), as this substituted benzimidazole has been shown to alter the pharmacokinetics of some drugs. CBZ serum levels were determined by high pressure liquid chromatography following oral administration of CBZ 400mg. Omeprazole treatment caused increases in CBZ blood levels and significantly prolonged the elimination half-life from 17.2 +/- 5.9 hours to 37.3 +/- 22.8 hours. Simultaneously, there was an increase in the area under the curve (AUC(0).(infinity) from 382.3 +/- 81.1 mu g/ml.h to 668.8 +/- 241.6 mu g/ml.h, while the CBZ clearance was decreased significantly from 20.7 +/- 3.4 ml/h/kg to 12.5 +/- 3.5 ml/h/kg. Other parameters such as maximum plasma drug concentration (C-max), time to reach maximum concentration (t(max)), and apparent volume of distribution at steady-state (V-ss) were, however, not altered by omeprazole treatment. The reduction in clearance and increase in half-life and AUC(0.infinity), values may be attributed to inhibition of CBZ oxidative metabolism by omeprazole.
引用
收藏
页码:8 / 12
页数:5
相关论文
共 25 条
[1]   EFFECT OF OMEPRAZOLE TREATMENT ON DIAZEPAM PLASMA-LEVELS IN SLOW VERSUS NORMAL RAPID METABOLIZERS OF OMEPRAZOLE [J].
ANDERSSON, T ;
CEDERBERG, C ;
EDVARDSSON, G ;
HEGGELUND, A ;
LUNDBORG, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (01) :79-85
[2]   OMEPRAZOLE DRUG-INTERACTION STUDIES [J].
ANDERSSON, T .
CLINICAL PHARMACOKINETICS, 1991, 21 (03) :195-212
[3]   SLOW OMEPRAZOLE METABOLIZERS ARE ALSO POOR S-MEPHENYTOIN HYDROXYLATORS [J].
ANDERSSON, T ;
REGARDH, CG ;
DAHLPUUSTINEN, ML ;
BERTILSSON, L .
THERAPEUTIC DRUG MONITORING, 1990, 12 (04) :415-416
[4]  
COHEN AF, 1991, BRIT J CLIN PHARMACO, V31, P565
[5]   THE RELATIONSHIP BETWEEN THE BINDING OF 2-NORMAL-ALKYLBENZIMIDAZOLES TO RAT HEPATIC-MICROSOMAL CYTOCHROME-P-450 AND THE INHIBITION OF MONOOXYGENATION [J].
DICKINS, M ;
BRIDGES, JW .
BIOCHEMICAL PHARMACOLOGY, 1982, 31 (07) :1315-1320
[6]   CARBAMAZEPINE METABOLISM IN MAN INDUCTION AND PHARMACOGENETIC ASPECTS [J].
EICHELBAUM, M ;
TOMSON, T ;
TYBRING, G ;
BERTILSSON, L .
CLINICAL PHARMACOKINETICS, 1985, 10 (01) :80-90
[7]   INCREASED CARBAMAZEPINE PLASMA-CONCENTRATIONS AFTER FLUOXETINE COADMINISTRATION [J].
GRIMSLEY, SR ;
JANN, MW ;
CARTER, JG ;
DMELLO, AP ;
DSOUZA, MJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (01) :10-15
[8]   DRUGS OTHER THAN H-2-RECEPTOR ANTAGONISTS AS CLINICALLY IMPORTANT INHIBITORS OF DRUG-METABOLISM INVIVO [J].
GUGLER, R ;
JENSEN, JC .
PHARMACOLOGY & THERAPEUTICS, 1987, 33 (01) :133-137
[9]   OMEPRAZOLE INHIBITS OXIDATIVE DRUG-METABOLISM - STUDIES WITH DIAZEPAM AND PHENYTOIN INVIVO AND 7-ETHOXYCOUMARIN INVITRO [J].
GUGLER, R ;
JENSEN, JC .
GASTROENTEROLOGY, 1985, 89 (06) :1235-1241
[10]  
GUGLER R, 1984, LANCET, V1, P969